The bladder cancer market has seen a tremendous uptake of immune checkpoint inhibitors with their approval in the locally advanced / metastatic setting and, in the case of Merck & Co.’s Keytruda, BCG-unresponsive non-muscle-invasive disease. These therapies have significantly altered the treatment landscape for bladder cancer, particularly among the cisplatin-ineligible population. Notably, the entry of two novel agents for previously treated locally advanced or metastatic disease, Janssen’s first-in-class FGFR inhibitor Balversa (erdafitinib) for patients harboring susceptible FGFR genetic alterations, and Astellas / Seattle Genetics’ ADC Padcev (enfortumab vedotin-ejfv), further expands U.S. physicians’ armamentarium beyond standard treatment options.
- What percentage of non-muscle-invasive bladder cancer patients receive maintenance BCG therapy, and how does this percentage vary by stage and histologic grade?
- What is the uptake of immune checkpoint inhibitors in the United States across therapy lines? How are immune checkpoint inhibitors faring against older (e.g., platinum-based chemotherapy) and/or newer therapies (e.g., Balversa, Padcev)?
- How do drug-treatment rates vary across key patient populations and treatment lines?
- What are the main drivers of and obstacles to the treatment with key drugs for unresectable locally advanced or metastatic bladder cancer?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.